Advancements in BACE1 and non-peptide BACE1 inhibitors for Alzheimer's disease

Numerous theories exist for the pathogenesis of Alzheimer's disease (AD) but BACE1 is considered to be a prime therapeutic target for lowering cerebral AP concentrations in Alzheimer's disease and clinical development of BACE1 inhibitors is being intensely pursued. Considering the present scenario, efforts have been put forth to compile all the information relevant to BACE1 and recent developments in the discovery of its non-peptide inhibitors. The upcoming screening methods have been touched upon along with structure based approach for predicting activity of inhibitors of BACE1. This review would aid in research work undertaken by industry and academia as even after decades of earnest research effort, there are relatively few treatment options for patients suffering from Alzheimer's disease.